Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. It operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and a range of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services comprising screenings, medical tests, immunizations, and basic physical exams. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. This segment also performs prescription adjudication services for other PBMs; and offers integrated mail-order, specialty and compounding pharmacy, and infertility treatment services, as well as drug benefits under the federal government's Medicare Part D program. As of April 12, 2018, the company operated approximately 2,548 stores in 19 states. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Drug stores & proprietary stores
Sub-IndustryDrug Retail
SectorRetail/Wholesale
Current SymbolNYSE:RAD
Previous Symbol
CUSIP76775410
Phone717-761-2633
Debt
Debt-to-Equity Ratio2.41
Current Ratio1.62
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio-49.18
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.53 billion
Price / Sales0.05
Cash Flow$0.5698 per share
Price / Cash Flow1.72
Book Value$1.50 per share
Price / Book0.65
Profitability
EPS (Most Recent Fiscal Year)($0.02)
Net Income$943.47 million
Net Margins3.26%
Return on Equity-1.97%
Return on Assets-0.30%
Miscellaneous
Employees59,000
Outstanding Shares1,066,570,000
Market Cap$1.08 billion
OptionableOptionable
Rite Aid (NYSE:RAD) Frequently Asked Questions
What is Rite Aid's stock symbol?
Rite Aid trades on the New York Stock Exchange (NYSE) under the ticker symbol "RAD."
How were Rite Aid's earnings last quarter?
Rite Aid Co. (NYSE:RAD) announced its quarterly earnings data on Thursday, September, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $5.42 billion for the quarter, compared to the consensus estimate of $5.36 billion. Rite Aid had a net margin of 3.26% and a negative return on equity of 1.97%. The company's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. View Rite Aid's Earnings History.
When is Rite Aid's next earnings date?
What guidance has Rite Aid issued on next quarter's earnings?
Rite Aid updated its FY19 earnings guidance on Thursday, September, 27th. The company provided earnings per share (EPS) guidance of ($0.03) - $0.01 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.03). The company issued revenue guidance of $21.7-22.1 billion, compared to the consensus revenue estimate of $21.79 billion.
What price target have analysts set for RAD?
6 brokerages have issued 1 year target prices for Rite Aid's shares. Their predictions range from $1.00 to $6.00. On average, they anticipate Rite Aid's stock price to reach $2.0833 in the next year. This suggests a possible upside of 112.6% from the stock's current price. View Analyst Price Targets for Rite Aid.
What is the consensus analysts' recommendation for Rite Aid?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rite Aid in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rite Aid.
Has Rite Aid been receiving favorable news coverage?
Media stories about RAD stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rite Aid earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Rite Aid?
Rite Aid saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 123,723,066 shares, a decline of 12.2% from the October 31st total of 140,891,676 shares. Based on an average daily trading volume, of 10,585,359 shares, the days-to-cover ratio is currently 11.7 days. Currently, 11.7% of the shares of the company are short sold. View Rite Aid's Current Options Chain.
Who are some of Rite Aid's key competitors?
Who are Rite Aid's key executives?
Rite Aid's management team includes the folowing people:
- Mr. John T. Standley, Chairman & CEO (Age 55)
- Mr. Kermit Ray Crawford, Pres & COO (Age 59)
- Mr. Darren Wayne Karst, Sr. EVP, CFO & Chief Admin. Officer (Age 58)
- Ms. Jocelyn Zazyczny Konrad, Exec. VP of Pharmacy (Age 48)
- Mr. Bryan B. Everett, Chief Operating Officer of Rite Aid Stores (Age 45)
Who are Rite Aid's major shareholders?
Rite Aid's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.84%), Franklin Resources Inc. (4.66%), Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp (2.19%), Dimensional Fund Advisors LP (0.57%), Bank of New York Mellon Corp (0.51%) and Morgan Stanley (0.30%). View Institutional Ownership Trends for Rite Aid.
Which major investors are selling Rite Aid stock?
RAD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Morgan Stanley, Franklin Resources Inc., Alliancebernstein L.P., Dimensional Fund Advisors LP, TIAA CREF Investment Management LLC and DLD Asset Management LP. View Insider Buying and Selling for Rite Aid.
Which major investors are buying Rite Aid stock?
RAD stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Kepos Capital LP, Kepos Capital LP, Laurion Capital Management LP, Creative Planning, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, AQR Capital Management LLC and PARK CIRCLE Co. View Insider Buying and Selling for Rite Aid.
How do I buy shares of Rite Aid?
Shares of RAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rite Aid's stock price today?
One share of RAD stock can currently be purchased for approximately $0.9801.
How big of a company is Rite Aid?
Rite Aid has a market capitalization of $1.08 billion and generates $21.53 billion in revenue each year. The company earns $943.47 million in net income (profit) each year or ($0.02) on an earnings per share basis. Rite Aid employs 59,000 workers across the globe.
What is Rite Aid's official website?
How can I contact Rite Aid?
Rite Aid's mailing address is 30 Hunter Lane, Camp Hill PA, 17105. The company can be reached via phone at 717-761-2633 or via email at [email protected]
MarketBeat Community Rating for Rite Aid (NYSE RAD)
MarketBeat's community ratings are surveys of what our community members think about Rite Aid and other stocks. Vote "Outperform" if you believe RAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
